The emerging role of PET-CT scan after radical prostatectomy: still a long way to go
Mené sur 50 patients atteints d'un cancer de la prostate avec récidive biochimique précoce après une prostatectomie radicale (durée médiane de suivi : 8 mois), cet essai compare, du point de vue des taux de détection, l'efficacité de deux techniques de tomographie numérique par émission de positrons, l'une à base de 18F-fluciclovine, l'autre ciblant l'antigène membranaire spécifique de la prostate
The management of biochemical recurrence after radical prostatectomy is a common challenge for urologists and radiation oncologists, because about 30% of patients have an increase in prostate-specific antigen (PSA) concentrations after surgical treatment. However, the outcome of these patients is not always poor, varying substantially according to the site and the extent of recurrence. In this context, the role of imaging is of the utmost importance to establish the real burden of recurrent disease. The increasing use of PET-CT has led to a shift towards early detection of low-volume metastatic prostate cancer, whereas several novel and promising PET tracers have been reported. However, no prospective clinical trials had tested the superiority of one tracer over the others in terms of diagnostic accuracy.
The Lancet Oncology , commentaire, 2018